Skip to main content
Equibles
AGTX logo

AGTX · Agentix Corp.

Track AGTX — free

Use AGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.02 At close · Sep 7
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$801,339
Shares
40.07M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.02 Open$0.02 Day$0.02–0.02 52W close$0.02–0.05 Avg vol 30d41K Short int18 · 0.0% float · 1.0d Short vol100% DataMar 2020–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$417,486
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-35.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.52
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −68%
below
Price vs 50-day avg −46%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 9%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −47%
trailing
6-month return +11%
trailing
YTD return −47%
this year
Relative strength −4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +38.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 18
low risk · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth 0%
Y/Y
Free cash flow $-109.9K
Quant / Vol
risk profile
Very High
Volatility 470%
annualized · 1-yr
Max drawdown −95%
past year
ATR 25.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−68% Bearish
Price vs 50-day avg
−46% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +38.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 9% Range high $0
vs 200-day avg -68% vs 50-day avg -46%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AGTX
Agentix Corp.
this stock
$801,339 -46.7% -100.0% — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.06B +13.9% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $79.83B +2.3% +20.8% 19.2 2.5%
ARGX
Argenx SE
 $60.93B +18.4% — — 2.0%
CSLLY
Csl Ltd
 $59.64B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
18
Days to cover
1.0d
Change
+5 sh
View
Short Volume
Short vol %
100%
As of
Aug 12, 2026
Short Total
View
Fails to Deliver
FTD shares
6.1K
Value
$304
As of
Jan 26, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-485.6K
EPS diluted
$-0.01
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 10, 2026
This year
3
View
Exempt Offerings
Offering
$4.0M
Filed
Feb 11, 2021
View

Performance

5D 20D 120D MTD YTD
AGTX +0.0% -47.4% +11.1% +0.0% -46.7%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -0.1% -47.0% -4.0% -0.4% -59.6%
Key facts CIK 1603345 Visit website